Assessment of response and toxicity
Tumors, tumor
TUMORS, SECONDARY, TUMOR
The primary endpoint was pCR. The secondary endpoints were clinical response rate (RR), breast-conserving rate, assessment of tumor-infiltrating lymphocytes (TILs), Secreted Protein Acidic and Rich in Cysteine (SPARC) in biopsy samples, and safety. Clinical tumor response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 using computed tomography or magnetic resonance imaging [